| Abstract: | This study aimed to analyze the clinical efficacy and safety of itraconazole.We investigated 68 patients with invasive fungal infections (IFI) in emergency intensive care unit (EICU). A retrospective analysis was performed in patients with IFI who were treated in the authors’ institution, a grade III first class hospital in Beijing, China, between Feb. 2013 and Feb. 2015. The age of patients ranged from 35 to 90 years old with the mean age of (75.1±11.1) years old. The study population comprised 36 male and 32 female patients. Total response rate was 60.3%. The response rates in definitive diagnosis, clinical diagnosis and presumed diagnosis were 33.3%, 59.5% and 65.2%, respectively (P<0.05). The empirical treatment should be provided for patients with presumed diagnosis as earlier as possible. Eleven (16.2%) cases had adverse drug event (ADE) during treatment. The main signs were hepatic functional impairment and hypokalemia of ADE. The clinical efficacy and safety of intravenous itraconazole were precisely assessed. To reduce the adverse drug reaction (ADR), hepatic and renal function and other biochemical criterion should be closely monitored. |
